By Associate Professor Mandy Ballinger

Book Chapters

Lin FP; Tran M; Thavaneswaran S; Grady JP; Kansara M; Chan J; Ballinger ML; Simes J; Thomas DM, 2025, 'Automating Precision Oncology Literature Curation: A Decision Tree Approach Using Large Language Models', in , pp. 248 - 252, http://dx.doi.org/10.3233/SHTI250839

Journal articles

Dwarte TM; Alli R; Srinivasa S; Noon F; Perera Kimmantudawage S; Gordon L; Beshay V; Joshua AM; Ruiz Araujo R; Jalilian C; Thomas DM; Smith MJ; Winship I; Ballinger ML; Li M; Tucker KM; Courtney EK, 2026, 'Challenging interpretation of low-level PTCH1 mosaicism in patients with clinically diagnosed Gorlin syndrome: a case series and review of the literature', Hereditary Cancer in Clinical Practice, 24, http://dx.doi.org/10.1186/s13053-026-00332-3

Hersch J; O’Hara L; Butow P; Ballinger M; Laidsaar-Powell R; Bartley N; McCaffery K; Latin A; Cockburn C; Delaney C; Tucker KM; Juraskova I, 2026, 'Development of a question prompt list to support Consent for Genomic Testing (CoGenT) and research', Human Genetics, 145, http://dx.doi.org/10.1007/s00439-026-02839-0

Zaheed M; Signal B; Hooshmand K; Walwyn K; Tucker K; Ballinger ML; Thomas DM, 2026, 'Clinically actionable cancer and non-cancer risk genes identified by whole genome sequencing (WGS) in early-onset tumours (EOT).', Journal of Clinical Oncology, 44, pp. 170 - 170, http://dx.doi.org/10.1200/jco.2026.44.19_suppl.170

Cote GM; Aberoumand M; Choy E; Sebastian L; Mazzola E; Grimison P; Merriam P; Ballinger M; Thavaneswaran S; Lin F; Grady JP; Millward M; Brown MP; Harrup R; Espinoza D; Demetri G; Littlefield BA; Simes RJ; George S; Thomas D, 2026, 'A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma', Clinical Cancer Research, 32, pp. 2206 - 2213, http://dx.doi.org/10.1158/1078-0432.CCR-25-3362

Rafati M; Guenther LM; Egolf LE; Gianferante M; Kim J; Wang K; Zhu B; Spector LG; Anderson N; Janeway KA; Barkauskas DA; Hawkins DS; Patiño-Garcia A; Lupo PJ; Scheurer ME; Morton L; Armstrong GT; Sapkota Y; Gramatges MM; Serra M; Hattinger C; Scotlandi K; Andrulis IL; Wunder JS; Ballinger ML; Thomas DM; Yeager M; Dean M; Stewart DR; Vogt A; Liu J; Hicks BD; Huang WY; Landi MT; Lori A; Diver WR; Savage SA; Chanock SJ; Mirabello L, 2026, 'SMARCAL1 is a new osteosarcoma predisposition gene', Journal of the National Cancer Institute, 118, pp. 1120 - 1125, http://dx.doi.org/10.1093/jnci/djaf278

Lin FP; Thavaneswaran S; Grady JP; Napier CE; Kansara M; Sebastian L; Kee D; Desai J; Zaheed M; Chinchen S; Oakes SR; Blackburn J; Scott HS; Glover A; Fox SB; Goldstein D; Leo P; Amanuel B; Mersiades A; Millward M; Brown MP; Charakidis M; Pokorny AMJ; Craft P; Espinoza D; Grimison P; Harrup R; Joshua AM; O'byrne K; Lee CK; Cowley MJ; Ballinger ML; Simes J; Thomas DM, 2026, 'Genomic Therapy Matching in Rare and Refractory Cancers', JAMA Oncology, 12, pp. 458 - 467, http://dx.doi.org/10.1001/jamaoncol.2026.0127

Nagrial A; Carlino MS; Gunjur A; Brown MP; Harris S; Underhill C; Zielinski R; Kee D; Lam W-S; Chan H; Harrup R; So J; Collins IM; Michael M; Chionh F; Uy C; Mariadason J; Torres J; Ballinger ML; Grady JP; Tavancheh E; Palmer J; Thomas DM; Wilkie K; Cebon J; Klein O, 2026, 'Nivolumab and ipilimumab combination treatment in patients with advanced intrahepatic cholangiocarcinoma and gallbladder cancer: Results from the phase II MoST-CIRCUIT trial.', Clin Cancer Res, http://dx.doi.org/10.1158/1078-0432.CCR-25-4009

Best MC; Descallar J; Simpson G; Napier CE; Bartley N; Ballinger ML; Goldstein D; Thomas DM; Tucker KM; Butow P, 2026, 'Impact of Spiritual Wellbeing in Advanced Cancer Patients Receiving Genomic Test Results', Psycho Oncology, 35, pp. e70471, http://dx.doi.org/10.1002/pon.70471

Koh B; Thavaneswaran S; Lin F; Grady J; Maddula M; Haghighi KS; Kansara M; Huang ML; Ballinger ML; Simes J; Thomas DM; Goldstein D, 2026, 'Exceptional Response to Durvalumab and Tremelimumab in Pancreatic Acinar Cell Carcinoma With Ultramutated Phenotype Associated With a DNA Polymerase-ε Mutation', JCO Precision Oncology, 10, http://dx.doi.org/10.1200/PO-25-01003

Carlino MS; Gao B; Michael M; Marshall H; Gunjur A; Chan H; Zielinski R; So J; Harris SJ; Kee D; Collins IM; Lam WS; Lyle M; Underhill C; Brown MP; Harrup R; Wong SF; Grady J; Ballinger M; Tavancheh E; Thomas DM; Palmer J; Wilkie K; Cebon J; Klein O, 2026, 'Nivolumab and Ipilimumab in Advanced Mismatch Repair–Deficient/Microsatellite Instability–High Noncolorectal Cancers: A Nonrandomized Clinical Trial', JAMA Oncology, 12, pp. 39 - 47, http://dx.doi.org/10.1001/jamaoncol.2025.4721

Siu DHW; Lin FPY; Thomas DM; Thavaneswaran S; Espinoza D; Chinchen S; Ballinger ML; Simes RJ; Lee CK, 2026, 'Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST program', Future Oncology, http://dx.doi.org/10.1080/14796694.2026.2688570

Southi N; Sim H-W; Grady J; Ballinger M; Thomas D; Thavaneswaran S, 2026, '145P Characterising homologous recombination deficiencies in gliomas', ESMO Open, 11, pp. 106288 - 106288, http://dx.doi.org/10.1016/j.esmoop.2026.106288

Liang S; Kennedy E; Gale N; Watson P; Ramanathan M; Shinde A; McKay S; Torres-Robles A; Li Z; Chan J; Jones H; Ballinger ML; Butow P; Goldstein D; Leaney K; Middleton S; Morrow A; Thomas DM; Tucker KM; Zaheed M; Parkinson B; Lin F; Taylor N; Torres Robles A, 2025, 'Implementation of precision medicine in treating non-communicable diseases: a systematic review', Journal of Translational Medicine, 23, pp. 1174, http://dx.doi.org/10.1186/s12967-025-07201-y

Hersch J; O'Hara L; Juraskova I; Laidsaar-Powell R; Bartley N; Gillies K; Ballinger M; Wang W; Butow P, 2025, 'Interventions to support patient decision making about taking part in health research: A systematic review', Patient Education and Counseling, 141, http://dx.doi.org/10.1016/j.pec.2025.109339

Liang S; McKay S; Lin F; Zaheed M; Morrow A; Douglas B; Chan J; Monaghan H; Chan P; Kennedy E; Tyedmers E; Walker S; Leaney K; Napier CE; Middleton S; Butow P; Williams R; Parkinson B; Ballinger ML; Tucker K; Goldstein D; Thomas D; Taylor N, 2025, 'Integration of precision medicine into routine cancer care—protocol for the Precision Care Initiative: a research programme of effectiveness-implementation hybrid trials', BMJ Open, 15, http://dx.doi.org/10.1136/bmjopen-2024-090270

Gao B; Carlino MS; Michael M; Underhill C; Marshall H; Gunjur A; So J; Kee D; Antill Y; Lam WS; Chan H; Harrup R; Hamilton A; Grady J; Ballinger M; Tavancheh E; Yoon WH; Palmer J; Thomas D; Wilkie K; Cebon J; Klein O, 2025, 'Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical Trial', JAMA Oncology, 11, pp. 982 - 989, http://dx.doi.org/10.1001/jamaoncol.2025.1916

Spencer S; Ye W; Napier C; Lin FP-Y; Thomas DM; Chan R; Ballinger ML; Morton RL; Berber S; Zou D; Peng S, 2025, 'Clinical and economic value of comprehensive genomic profiling in patients with advanced solid cancers using Australian real-world data: Preliminary analyses.', JOURNAL OF CLINICAL ONCOLOGY, 43, pp. e15084 - e15084, http://dx.doi.org/10.1200/JCO.2025.43.16_suppl.e15084

Lin FP-Y; Goldstein D; Grady JP; Napier C; Thavaneswaran S; Pitiyarachchi O; Kansara M; Chantrill LA; Sjoquist K; Thornton K; Raina A; Magenau A; Simes J; Ballinger ML; Sharbeen G; Timpson P; Pajic M; Phillips P; Thomas DM, 2025, 'Genomic and outcome analysis of recurrent versus de novo metastatic pancreatic ductal adenocarcinoma (PDAC) receiving systemic therapy: Results from the Australian MoST and CaSP screening programs.', JOURNAL OF CLINICAL ONCOLOGY, 43, pp. 4120 - 4120, http://dx.doi.org/10.1200/JCO.2025.43.16_suppl.4120

Lin FP-Y; Huang ML; Grady JP; Thavaneswaran S; Kansara M; Napier C; Ballinger ML; Simes J; Thomas DM, 2025, 'Machine learning-based classification of cancer types using genomic profiling data from the Australian Molecular Screening and Therapeutics (MoST) program.', JOURNAL OF CLINICAL ONCOLOGY, 43, pp. e13683 - e13683, http://dx.doi.org/10.1200/JCO.2025.43.16_suppl.e13683

Kohlmann W; Curtin K; Madsen MJ; Camp NJ; Jeter JM; Ballinger ML; Thomas DM; Garber JE; Schiffman JD, 2025, 'Population-based assessment of leiomyosarcoma (LMS) and cancers in the Li-Fraumeni syndrome (LFS) spectrum: Implications for genetic testing criteria', JOURNAL OF CLINICAL ONCOLOGY, 43, http://dx.doi.org/10.1200/JCO.2025.43.16_suppl.11570

McParland K; Koh ES; Kong B; Sim HW; Thavaneswaran S; Yip S; Barnes EH; Ballinger ML; Thomas DM; De Abreu Lourenco R; Simes J; Sebastian L; Wheeler PJ; Spyridopoulos D; Hawkins C; Pitz M; O'Callaghan C; Gan HK, 2025, 'Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2): study protocol for a phase 2, prospective, multicentre, open-label, multiarm, biomarker-directed, signal-seeking, umbrella, clinical trial for recurrent IDH mutant, grade 2/3 glioma', BMJ Open, 15, http://dx.doi.org/10.1136/BMJOPEN-2024-087922

Novis E; Glover A; Grady JP; Silvestri A; Thavaneswaran S; Lin F; Ballinger ML; Thomas DM, 2025, 'Oncogenic mutations in the TP53 and PI-3 kinase/AKT pathway are independent predictors of survival for advanced thyroid cancer: Analysis from the Molecular Screening and Therapeutics (MoST) program', Surgery United States, 177, http://dx.doi.org/10.1016/j.surg.2024.05.058

Ballinger ML; Thomas DM, 2025, 'POT1 clinical risk management is an open question', European Journal of Human Genetics, 33, pp. 3 - 4, http://dx.doi.org/10.1038/s41431-024-01676-x

Kansara M; Thavaneswaran S; Lin FP; Kok P-S; Grady J; Thomas H; Corpuz T; Mundra P; Lu J; Ballinger M; Desai J; Harrup RA; Craft P; Charakidis M; O'Byrne KJ; Selva-Nayagam S; Millwar M; Grimiso P; Simes J; Thomas D, 2025, 'A phase II trial of palbociclib and avelumab in advanced solid tumours with CDK4/6 pathway alterations', ANNALS OF ONCOLOGY, 36, http://dx.doi.org/10.1016/j.annonc.2025.08.2175

Connolly LA; Bucio-Noble D; Koh J; Sykes E; McNamee N; Singh A; Aref A; Ye L; Karim R; Maclean F; Bhadri VA; Nassif Haddad EF; Ingram DR; Morey RR; Wani KM; Lazar AJ; Thomas D; Ballinger M; Simes J; Scott C; Barker HE; Milesi B; Ratnayake G; Cain JE; Zhukova N; Hains P; Horvath L; Grimison PS; Robinson P; Reddel R, 2025, 'EXPRESSION OF EMERGING THERAPEUTIC TARGET B7-H3 IN SARCOMA - A MASS SPECTROMETRY-BASED PROTEOMIC ANALYSIS OF >1000 SARCOMA SAMPLES', ESMO Rare Cancers, 4, pp. 100050 - 100050, http://dx.doi.org/10.1016/j.esmorc.2025.100050

Ballinger M; Zaheed M; Carpenter E; Napier C; Cops E; Ferris N; Moodie K; Milner B; Moses D; Dwarte T; Poplawski N; Dow E; Tucker K; Trainer A; James P; Thomas D, 2025, 'LONG TERM SURVEILLANCE OUTCOMES IN SARCOMA PREDISPOSITION SYNDROMES', ESMO Rare Cancers, 4, pp. 100044 - 100044, http://dx.doi.org/10.1016/j.esmorc.2025.100044

Pavlakis N; Lee CK; Ballinger ML; Brown CSB; Grady JP; Lin F; Thavaneswaran S; Mersiades AJ; Di-Xin Zhou D; Lee J; John T; Napier CE; Cummins MM; Collignon E; Sebastian L; Turnbull OMH; Simes J; Thomas DM; Solomon BJ, 2025, 'P2.06.61 ASPiRATION. Australian Nationwide Cohort Study to Assess Impact of Comprehensive Genomic Profiling in Metastatic Lung Cancer', Journal of Thoracic Oncology, 20, pp. S318 - S319, http://dx.doi.org/10.1016/j.jtho.2025.09.595

Hersch J; Butow P; Latin A; O'Hara L; Ballinger ML; Laidsaar-Powell R; Bartley N; Cockburn C; McCaffery K; Juraskova I, 2025, 'P453: Improving COnsent in cancer GENomic Testing (CoGenT): codesigning a novel dynamic platform', The Breast, 80, pp. 104261 - 104261, http://dx.doi.org/10.1016/j.breast.2025.104261

Kansara M; Lin FP; Thavaneswaran S; Huang ML; Tran M; Corpuz T; Lu J; Espinoza D; Chinchen S; Ballinger M; Grimison P; Andelkovic V; Dow EG; Desai J; Simes J; Thomas D, 2025, 'Phase II trial of tildrakizumab in treatment-refractory bone and soft tissue sarcomas', ANNALS OF ONCOLOGY, 36, http://dx.doi.org/10.1016/j.annonc.2025.08.3325

Collet L; Telouk P; Albarede F; Girodet M; Maqua C; Rogasik M; Ducimetière F; Tabone-Eglinger S; Brahmi M; Dufresne A; Thomas DM; Ballinger ML; Blay JY; Ray-Coquard I, 2024, 'Connecting the changing trace elements spectrum and survival in sarcoma: a pilot study', Metabolomics, 20, http://dx.doi.org/10.1007/s11306-024-02178-z

Gianferante DM; Moore A; Spector LG; Wheeler W; Yang T; Hubbard A; Gorlick R; Patiño-Garcia A; Lecanda F; Flanagan AM; Amary F; Andrulis IL; Wunder JS; Thomas DM; Ballinger ML; Serra M; Hattinger C; Demerath E; Johnson W; Birmann BM; De Vivo I; Giles G; Teras LR; Arslan A; Vermeulen R; Sample J; Freedman ND; Huang WY; Chanock SJ; Savage SA; Berndt SI; Mirabello L, 2024, 'Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma', Cancer Epidemiology, 92, http://dx.doi.org/10.1016/j.canep.2023.102432

Best MC; Butow P; Savard J; Newson AJ; Campbell R; Vatter S; Napier CE; Bartley N; Tucker K; Ballinger ML; Thomas DM; Butow P; Newson AJ; Tucker K; Juraskova I; Schlub T; Davies G; Meiser B; Goldstein D, 2024, 'From ownership to custodianship of tumor biopsy tissue in genomic testing: A mixed methods study of patient views', Oncologist, 29, pp. e1169 - e1179, http://dx.doi.org/10.1093/oncolo/oyae074

Mirabello L; Egolf LE; Zhu B; Gianferante DM; Wang K; Li SA; Machiela MJ; Spector LG; Schiffman JD; Sabo A; Renwick A; Martin-Giacalone B; Scheurer ME; Plon S; Hawkins D; Venkatramani R; Stewart D; Morton LM; Hudson MM; Armstrong GT; Bhatia S; Dean M; Janeway KA; Patino-Garcia A; Lecanda F; Serra M; Hattinger C; Scotlandi K; Flanagan AM; Amary F; Andrulis IL; Wunder JS; Ballinger ML; Thomas DM; Delattre O; Hubbard AK; Liu J; Luo W; Hicks BD; Yeager M; Rafati M; Huang W-Y; Landi MT; Lori A; Diver R; Savage SA; Chanock SJ; Lupo PJ, 2024, 'Underlying germline genetic architecture of pediatric sarcomas: Evaluating the role of common and rare variants in 4,160 patients', CANCER RESEARCH, 84, http://dx.doi.org/10.1158/1538-7445.AM2024-775

Mersiades AJ; Solomon Benjamin J; Thomas David M; Lee CK; Cummins MM; Sebastian L; Ballinger ML; Collignon E; Turnbull OMH; Yip S; Morton RL; Brown C; Wheeler PJ; Itchins M; Simes RJ; Pavlakis N, 2024, 'ASPiRATION: Australian Observational Cohort Study of Comprehensive Genomic Profiling in Metastatic Lung Cancer Tissue', Future Oncology, 20, pp. 361 - 371, http://dx.doi.org/10.2217/fon-2023-0366

Fortuno C; Feng BJ; Carroll C; Innella G; Kohlmann W; Lázaro C; Brunet J; Feliubadaló L; Iglesias S; Menéndez M; Teulé A; Ballinger ML; Thomas DM; Campbell A; Field M; Harris M; Kirk J; Pachter N; Poplawski N; Susman R; Tucker K; Wallis M; Williams R; Cops E; Goldgar D; Investigators KCF; James PA; Spurdle AB, 2024, 'Cancer Risks Associated With TP53 Pathogenic Variants: Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome Spectrum', JCO Precision Oncology, 8, http://dx.doi.org/10.1200/PO.23.00453

Sargen MR; Kim J; Haley JS; Barker HP; Mundra PA; Ballinger ML; Thomas DM; Carey DJ; Goldstein AM; Stewart DR, 2024, 'Increased frequency of CHEK2 germline pathogenic variants among individuals with dermatofibrosarcoma protuberans', Genetics in Medicine Open, 2, http://dx.doi.org/10.1016/j.gimo.2024.101895

Hetherington K; Wakefield CE; McGill BC; Tucker KM; Donoghoe MW; Daly R; Hunter JD; Ballinger M; Fuentes-Bolanos NA; Ziegler DS, 2024, 'When genetics and pediatric cancer collide: Understanding and optimizing families' experiences', Neuro Oncology Advances, 6, http://dx.doi.org/10.1093/noajnl/vdae133

Ng JY; Warwick L; Craft P; Austen L; Ashford B; Gorddard N; Ballinger ML; Thomas DM; Blombery P; Tucker K; Polizzotto MN, 2023, 'Myelodysplastic syndrome and multiple solid tumours in an individual with compound heterozygous deleterious FANCM variants: A case report and review of the literature', British Journal of Haematology, 203, pp. 481 - 484, http://dx.doi.org/10.1111/bjh.19059

Harrison C; Bartley N; Jacobs C; Best M; Vatter S; Meiser B; Ballinger ML; Thomas DM; Butow P, 2023, 'Family communication and results disclosure after germline sequencing: A mixed methods study', Patient Education and Counseling, 114, http://dx.doi.org/10.1016/j.pec.2023.107800

Thavaneswaran S; Kansara M; Lin F; Espinoza D; Grady JP; Lee CK; Ballinger ML; Sebastian L; Corpuz T; Qiu MR; Mundra P; Bailey CG; Schmitz U; Simes J; Joshua AM; Thomas DM, 2023, 'A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations', British Journal of Cancer, 129, pp. 475 - 485, http://dx.doi.org/10.1038/s41416-023-02311-0

Kansara M; Lin FP-Y; Thavaneswaran S; Napier CE; Grady JP; Ballinger ML; Simes J; Thomas DM, 2023, 'Genomic alterations associated with response to immune checkpoint inhibitors in rare cancers: A biomarker exploration study from the Australian Molecular Screening and Therapeutics (MoST) Program.', Journal of Clinical Oncology, 41, pp. 2594 - 2594, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.2594

Thavaneswaran S; Lin FP-Y; Napier CE; Grady JP; Ballinger ML; Kansara M; Grimison PS; Pavlakis N; Wong MK; Sjoquist KM; Goldstein D; Chantrill LA; Simes J; Thomas DM, 2023, 'Genomic targetability and survival outcomes of biliary tract cancers (BTC): A retrospective cohort study of the Australian Molecular Screening and Therapeutics (MoST) program', JOURNAL OF CLINICAL ONCOLOGY, 41, http://dx.doi.org/10.1200/JCO.2023.41.16_suppl.4093

Lin FP-Y; Thavaneswaran S; Napier CE; Grady JP; Kansara M; Sebastian L; Kee D; Zaheed M; Millward M; Brown MP; Charakidis M; Craft PS; Grimison PS; Harrup RA; O'Byrne KJ; Desai J; Lee CK; Ballinger ML; Simes J; Thomas DM, 2023, 'Genomic therapy matching in rare and refractory cancers: Updated results from a retrospective cohort study in the Molecular Screening and Therapeutic (MoST) program', JOURNAL OF CLINICAL ONCOLOGY, 41, http://dx.doi.org/10.1200/JCO.2023.41.16_suppl.1540

Zaheed M; Napier CE; Cops EJ; Ferris N; Moodie K; Milner B; Moses D; Poplawski N; Dow EG; Harris M; Tucker K; Trainer A; James P; Thomas DM; Ballinger ML, 2023, 'Long-term clinical and psychosocial outcomes of surveillance in Li Fraumeni syndrome.', JOURNAL OF CLINICAL ONCOLOGY, 41, http://dx.doi.org/10.1200/JCO.2023.41.16_suppl.10578

Kee D; Lin FP-Y; Thavaneswaran S; Napier CE; Harrison ML; Beale PJ; Lynch J; Davis AJ; Ananda S; Lombard JM; Friedlander M; Kansara M; Sebastian L; Lee CK; Ballinger ML; Simes J; Thomas DM, 2023, 'Molecular tumor profiling and therapy selection in advanced gynecological cancers: A retrospective cohort analysis from the Australian Molecular Screening and Therapeutics (MoST) Program', JOURNAL OF CLINICAL ONCOLOGY, 41, http://dx.doi.org/10.1200/JCO.2023.41.16_suppl.5526

Ballinger ML; Pattnaik S; Mundra PA; Zaheed M; Rath E; Priestley P; Baber J; Ray-Coquard I; Isambert N; Causeret S; van der Graaf WTA; Puri A; Duffaud F; Le Cesne A; Seddon B; Chandrasekar C; Schiffman JD; Brohl AS; James PA; Kurtz JE; Penel N; Myklebost O; Meza-Zepeda LA; Pickett H; Kansara M; Waddell N; Kondrashova O; Pearson JV; Barbour AP; Li S; Nguyen TL; Fatkin D; Graham RM; Giannoulatou E; Green MJ; Kaplan W; Ravishankar S; Copty J; Powell JE; Cuppen E; van Eijk K; Veldink J; Ahn JH; Kim JE; Lor Randall R; Tucker K; Judson I; Sarin R; Ludwig T; Genin E; Deleuze JF; Haber M; Marshall G; Cairns MJ; Blay JY; Thomas DM, 2023, 'Heritable defects in telomere and mitotic function selectively predispose to sarcomas', Science, 379, pp. 253 - 260, http://dx.doi.org/10.1126/science.abj4784

Best MC; Bartley N; Napier CE; Fisher A; Ballinger ML; Thomas DM; Goldstein D; Tucker K; Biesecker BB; Butow P, 2022, 'Return of comprehensive tumour genomic profiling results to advanced cancer patients: a qualitative study', Supportive Care in Cancer, 30, pp. 8201 - 8210, http://dx.doi.org/10.1007/s00520-022-07272-3

Butow P; Napier C; Campbell R; Bartley N; Best M; Ballinger ML, 2022, 'Validation of the Knowledge of Genome Sequencing (KOGS) scale in cancer patients', Patient Education and Counseling, 105, pp. 3110 - 3115, http://dx.doi.org/10.1016/j.pec.2022.06.009

Best MC; Butow P; Savard J; Jacobs C; Bartley N; Davies G; Napier CE; Ballinger ML; Thomas DM; Biesecker B; Tucker KM; Juraskova I; Meiser B; Schlub T; Newson AJ, 2022, 'Preferences for return of germline genome sequencing results for cancer patients and their genetic relatives in a research setting', European Journal of Human Genetics, 30, pp. 930 - 937, http://dx.doi.org/10.1038/s41431-022-01069-y

Back to profile page